Related Experiment Videos
[Is sentinel lymph node procedure in early-staged cutaneous melanoma really safe?]
1Service de chirurgie plastique et maxillofaciale, CHU de Dijon, 3, rue du Faubourg Raines, 21033 Dijon, France. otrost@caramail.com
Annales De Chirurgie Plastique Et Esthetique
|April 12, 2005
Summary
Sentinel lymph node biopsy (SLNB) for early-stage cutaneous melanoma is costly and invasive, leading to treatment delays and complications. This procedure offers no survival benefit over watchful waiting.
Area of Science:
- Oncology
- Surgical Pathology
Context:
- Early-stage cutaneous melanoma requires precise staging for optimal treatment.
- Sentinel lymph node biopsy (SLNB) is a procedure used to assess melanoma spread.
Purpose:
- To analyze the outcomes, complications, and costs associated with SLNB in early-stage cutaneous melanoma patients.
- To compare SLNB outcomes with a 'wait and watch' policy.
Summary:
- A prospective study of 45 early-stage cutaneous melanoma patients undergoing SLNB found excellent procedure sensibility on trunk and limbs, but lower on head and neck.
- Patients experienced a mean hospitalization of 3 days, 20 days of dressing care, and work inability dependent on interferon treatment.
- Complications, including seroma and local infections, occurred in 25% of patients, increasing healing time to 45 days and exacerbating inability. SLNB costs were significantly higher than watchful waiting.
Impact:
- SLNB is an expensive and invasive procedure with a high complication rate.
- The procedure can defer melanoma treatment, potentially impacting survival outcomes.
- Findings suggest SLNB may not be cost-effective or beneficial for all early-stage cutaneous melanoma cases compared to less invasive monitoring.